1. ABVX added to Nasdaq Biotechnology Index, enhancing its market visibility. 2. The inclusion reflects progress with obefazimod in Phase 3 trials. 3. The Nasdaq Biotechnology Index tracks biotech performance; ABVX meets criteria. 4. CFO highlights milestone for Abivax's growth and recognition in biotech. 5. Effective from December 22, 2025, prior to market open.
FAQ
Why Bullish?
Inclusion in a prominent index usually boosts visibility and investment interest. For example, companies like Moderna saw price surges upon such inclusions.
How important is it?
The index inclusion signifies increased institutional interest and perceived stability, critical for attracting new investors and analysts.
Why Short Term?
Immediate market reactions often follow index inclusions, enhancing liquidity and trading volume in the short term, similar to other biotech firms post-inclusion.
Abivax to Join Nasdaq Biotechnology Index
PARIS, France – December 18, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX), a clinical-stage biotechnology company, announced its upcoming addition to the Nasdaq Biotechnology Index (Nasdaq: NBI). This inclusion will be effective before the market opens on Monday, December 22, 2025. The company’s progress, particularly in advancing its lead candidate, obefazimod, underlines its growing significance in the biotechnology sector.
Significance of the Nasdaq Biotechnology Index Inclusion
Didier Blondel, Chief Financial Officer of Abivax, remarked, “Our inclusion in the Nasdaq Biotechnology Index marks a significant milestone for Abivax. It highlights the meaningful progress we’ve made as a company, particularly in advancing obefazimod through the successful Phase 3 ABTECT Induction trials for ulcerative colitis. This reflects the increased visibility and perception of Abivax within the global biotechnology community.”
About the Nasdaq Biotechnology Index
The Nasdaq Biotechnology Index is designed to monitor the performance of biotechnology and pharmaceutical companies listed on The Nasdaq Stock Market® based on the Industry Classification Benchmark. Companies included in the NBI must meet specific eligibility requirements, such as:
- Minimum market capitalization
- Average daily trading volume
- Public company seasoning
The index is reviewed annually in December and calculated using a modified capitalization-weighted methodology, ensuring that it accurately reflects the performance of the biotechnology sector.
Background on Abivax
Abivax is a clinical-stage biotechnology company dedicated to developing therapeutics that leverage the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. With operations in both France and the United States, Abivax’s flagship drug candidate, obefazimod (ABX464), is currently undergoing Phase 3 clinical trials aimed at treating moderately to severely active ulcerative colitis.
Learn More
For additional information about the Nasdaq Biotechnology Index, visit the official Nasdaq website: Nasdaq OMX Index Overview.